Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California. Show more
Location: 1599 Industrial Road, San Carlos, CA, 94070, United States | Website: https://biomeafusion.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
118.1M
52 Wk Range
$1.29 - $12.85
Previous Close
$1.65
Open
$1.63
Volume
1,642,385
Day Range
$1.57 - $1.68
Enterprise Value
77.58M
Cash
56.22M
Avg Qtr Burn
-25.03M
Insider Ownership
7.97%
Institutional Own.
41.54%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMF-219 (icovamenib) + GLP-1-based therapy Details Severe insulin-deficient type 2 diabetes patients | Phase 2b Initiation | |
Phase 2 Data readout | ||
Icovamenib + GLP-1 based therapy Details Type 2 diabetes | Phase 2 Initiation | |
BMF-219 (icovamenib) Details Type 2 diabetes | Phase 1/2 Update | |
BMF-650 (GLP-1 RA) Details Obese, otherwise healthy volunteers | Phase 1 Data readout | |
BMF-500 Details Leukemia | Phase 1 Update | |
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia | Failed Discontinued | |
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma | Failed Discontinued |